Informatie:
Fout:
ID
14491
Beschrijving
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults; ODM derived from: https://clinicaltrials.gov/show/NCT00649025
Link
https://clinicaltrials.gov/show/NCT00649025
Trefwoorden
Versies (1)
- 18-04-16 18-04-16 -
Houder van rechten
CC BY-NC 3.0
Geüploaded op
18 april 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Asthma NCT00649025
Eligibility Asthma NCT00649025
- StudyEvent: Eligibility
Similar models
Eligibility Asthma NCT00649025
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
age
Item
≥ age 12 years at the screening visit.
boolean
C0001779 (UMLS CUI [1])
history of asthma
Item
history of asthma for 12 months prior to the screening visit.
boolean
C0262926 (UMLS CUI [1,1])
C0004096 (UMLS CUI [1,2])
C0004096 (UMLS CUI [1,2])
inhaled corticosteroid
Item
documented use of an inhaled corticosteroid for at least 4 weeks prior to the screening visit.
boolean
C0586793 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
steroid requiring
Item
steroid-requiring patient
boolean
C0038317 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C1514873 (UMLS CUI [1,2])
fev1 and fev1 reversibility
Item
patients must demonstrate (1) an fev1 of 40% to 80% (inclusive) of predicted normal values at both the screening and baseline visits and (2) documented reversibility within 12 months of the screening visit, defined as a ≥ 15%
boolean
C0748133 (UMLS CUI [1])
C0748133 (UMLS CUI [2,1])
C0449261 (UMLS CUI [2,2])
C0748133 (UMLS CUI [2,1])
C0449261 (UMLS CUI [2,2])
exclusion criteria
Item
main exclusion criteria:
boolean
C0680251 (UMLS CUI [1])
life-threatening asthma
Item
life-threatening asthma within the past year or during the run-in period.
boolean
C0004096 (UMLS CUI [1,1])
C2826244 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
C2826244 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
systemic steroids
Item
history of systemic (oral or injectable) corticosteroid medication within 3 months before the screening visit.
boolean
C2825233 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
respiratory infection
Item
an upper or lower respiratory infection within 4 weeks prior to the screening visit or during the run-in period.
boolean
C0035243 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
pulmonary disease
Item
significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease [copd], cystic fibrosis, bronchiectasis).
boolean
C0024115 (UMLS CUI [1])
smoking history
Item
a smoking history equivalent to "10 pack years" (i.e., at least 1 pack of 20 cigarettes /day for 10 years or 10 packs/day for 1 year, etc.).
boolean
C1519384 (UMLS CUI [1])
C1277691 (UMLS CUI [2])
C1277691 (UMLS CUI [2])
current smoking history
Item
current smoking history within 12 months prior to the screening visit.
boolean
C1519384 (UMLS CUI [1])
previous exposure to flutiform
Item
previous exposure to flutiform
boolean
C3849509 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0332157 (UMLS CUI [1,3])
C0205156 (UMLS CUI [1,2])
C0332157 (UMLS CUI [1,3])